Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 7.19
+0.06 (0.84%)
At close: Aug 29, 2025
Shanghai MicuRx Pharmaceutical Company Description
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.
It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour.
Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Shanghai MicuRx Pharmaceutical Co., Ltd.
| Country | China |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Yuan Zhengyu |
Contact Details
Address: 53, Edison Road Shanghai China | |
| Phone | 86 21 5090 0550 |
| Website | micurxchina.com |
Stock Details
| Ticker Symbol | 688373 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuan Zhengyu Ph.D. | Chief Executive Officer and Chairman |
| Zhiyue Li | Director, Deputy GM and Chief Financial Officer |
| Xinghai Wang | Deputy GM and Chief Technology Officer |
| Hong Yuan | Deputy GM and Chief Clinical Officer |
| Dongming Zhao | Deputy GM and GM of Kerui Kaisi |
| Liang Lu | Chairman of the Supervisory Board, Director of the Quality and Compliance Department |
| Liu Jingian | Head of Corporate Chemistry |
| Wang Wen | Head of Biological Department |